Results 111 to 120 of about 259,973 (292)

The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines [PDF]

, 2009
Background and objective Tumor-associated PD-L1 expression was recently shown to promote T-cell apoptosis and proposed as a potential mechanism of immune evasion by tumors. On the basis of the ability of tumor-associated PD-L1 to mediate activated T-cell
Cheng CHEN, Chuanyong MU, Jian’an HUANG, Jing SUN, Qiuxia QU, Xueguang ZHANG, Yibei ZHU   +6 more
core  

Lack of PD-L1 Expression by iNKT Cells Improves the Course of Influenza A Infection [PDF]

, 2013
There is evidence indicating that invariant Natural Killer T (iNKT) cells play an important role in defense against influenza A virus (IAV). However, the effect of inhibitory receptor, programmed death-1 (PD-1), and its ligands, programmed death ligand ...
Akbari, Omid, Inn, Kyung Soo, Jung, Jae U., Khoo, Bryant, Lam, Jonathan, Lombardi, Vincent, Maazi, Hadi, Sharpe, Arlene Helen, Singh, Abinav K., Speak, Anneliese O.   +9 more
core   +3 more sources

A Reproducible and Scalable Process for High Yield Mesenchymal Stromal Cell Extracellular Vesicles Production

Advanced Materials Technologies, EarlyView.
Mesenchymal stem cell derived extracellular vesicles (MSC‐EVs) are a promising therapeutic tool for regenerative medicine. However, the field lacks a reproducible high‐yield production method to answer the quantities needed for clinical translation.
Christophe Wong, Elise Madec, Jeanne Volatron, Max Piffoux, Amanda K. A. Silva, Florence Gazeau, Jean‐Philippe Herbeuval, Thibaut Fourniols   +7 more
wiley   +1 more source

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

Frontiers in Immunology, 2017
The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the ...
Rachel M. Gibbons Johnson, Haidong Dong, Haidong Dong   +2 more
doaj   +1 more source

Association of Melanoma-Associated Antigen-A and Program-death ligand 1 Expression and Clinical Outcomes in Urothelial Carcinoma [PDF]

, 2019
Background: The melanoma-associated antigen-A (MAGE-A) and program-death ligand 1 (PD-L1) are present in urothelial carcinoma (UC). We aim to assess survival outcomes in patients with MAGE-A and PD-L1 expression.Methods: Analysis of MAGE-A and PD-L1 ...
Faiena, Izak
core  

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells [PDF]

, 2014
Programmed death ligand 1 (PD-L1) is an immunosuppressive molecule expressed by many cancer types, including a large proportion of head and neck cancers (HNC), and ligation of its receptor, programmed death 1 (PD-1), induces exhaustion of effector T ...
Concha-Benavente, Fernando, Ferris, Robert L   +1 more
core   +2 more sources

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source

Tailoring Vascular‐Immune Homeostasis via Manganese‐DNA Complex‐Armed Immunogenic Extracellular Vesicles for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang, Lihuan Shang, Xiaochun Chen, Xiangzhan Kong, Xiaojuan Wang, Linjia Jiang, Huiying Zhao, Yafeng Zhu, Cheng Huang, Shiyi Deng, Rui Zhang, Minghui Wang, Haoming Lin, Ping‐Pui Wong   +13 more
wiley   +1 more source

GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer

Heliyon
The programmed death-ligand 1 (PD-L1) on the surface of tumor cells binds to the receptor programmed cell death protein 1 (PD-1) on effector T cells, thereby inhibiting the anti-tumor immune response. Immune checkpoint blockade (ICB) therapy targeting PD-
Xue Sun, Mingen Lin, Ziyin Tian, Yan Ma, Lei Lv   +4 more
doaj   +1 more source